Osilodrostat
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endogenous Cushing Syndrome
Conditions
Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Trial Timeline
Jul 19, 2024 → Aug 1, 2027
NCT ID
NCT06430528About Osilodrostat
Osilodrostat is a pre-clinical stage product being developed by Recordati for Endogenous Cushing Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06430528. Target conditions include Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06430528 | Pre-clinical | Recruiting |
| NCT05633953 | Pre-clinical | Completed |
| NCT05382156 | Pre-clinical | Active |
| NCT03606408 | Phase 2 | Completed |
Competing Products
2 competing products in Endogenous Cushing Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intervention/Treatment | Recordati | Approved | 82 |
| Osilodrostat | Recordati | Pre-clinical | 20 |